Wong Ho Lun, Bendayan Reina, Rauth Andrew M, Li Yongqiang, Wu Xiao Yu
Leslie Dan Faculty of Pharmacy, 19 Russell Street, University of Toronto, Ontario, Canada M5S 2S2.
Adv Drug Deliv Rev. 2007 Jul 10;59(6):491-504. doi: 10.1016/j.addr.2007.04.008. Epub 2007 May 1.
The prospect of improved cancer chemotherapy using solid lipid nanoparticles (SLN) as a drug delivery system is promising. Several obstacles frequently encountered with anticancer compounds, such as normal tissue toxicity, poor specificity and stability and a high incidence of drug-resistant tumor cells, are at least partially overcome by delivering them using SLN. The emergence of the newer forms of SLN such as polymer-lipid hybrid nanoparticles, nanostructured lipid carriers and long-circulating SLN may further expand the role of this versatile drug carrier in cancer treatment. This review focuses on the current use of SLN for the encapsulation and delivery of cytotoxic anticancer compounds. It also discusses more recent trends in the use of SLN as vehicles for delivery of chemosensitizers and cytotoxic therapeutic molecules. It is anticipated that, in the near future, SLN will be further improved to deliver anticancer compounds in a more efficient, specific and safer manner.
使用固体脂质纳米粒（SLN）作为药物递送系统来改善癌症化疗的前景很广阔。抗癌化合物经常遇到的几个障碍，如正常组织毒性、特异性和稳定性差以及耐药肿瘤细胞的高发生率，通过使用SLN递送它们至少能部分克服。新型的SLN形式，如聚合物-脂质杂化纳米粒、纳米结构脂质载体和长循环SLN的出现，可能会进一步扩大这种多功能药物载体在癌症治疗中的作用。本综述重点关注SLN目前在封装和递送细胞毒性抗癌化合物方面的应用。它还讨论了SLN作为化学增敏剂和细胞毒性治疗分子递送载体的最新应用趋势。预计在不久的将来，SLN将得到进一步改进，以更高效、特异和安全的方式递送抗癌化合物。
